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The early use of local cortisone preparations in dermatologic therapy proved
quite disappointing (1, 2). Topical hydrocortisone preparations, however, have
been fairly effective in the treatment of certain acute inflammatory dermatoses,
particularly those in the eczema group (3—6). The striking therapeutic disparity
between these two hormones has suggested one of two explanations: that either
there are marked differences in percutaneous absorption of these compounds, or
that anti-inflammatory effects depend on hydrocortisone or its metabolites,
substances which the skin cannot produce from cortisone.
Since the penetration of hydrocortisone-4-C'4 throngh normal human skin
had been established by a previous study (7) identical with that now being
reported for cortisone-4-C'4, it appeared that an investigation of the percutane-
ous absorption of cortisone might add further to our knowledge of the physiology
and metabolism of these adrenal steroids in the skin.
METHOI)
The studies were performed on three hospitalized patients at bed rest. Sub-
ect * 1, a fifteen-year old girl with idiopathic thoracolnmbar scoliosis and
spondylolisthesis, had undergone surgery for spinal fusion. Subject *' 2 was a
sixty-six-year old woman with degenerative arthritis of the right hip recently
operated on for hip fusion. Subject 3 was a sixteen-year old girl who, like the
first patient, had undergone a spinal fusion procedure for progressive idiopathic
thoracolumbar scoliosis. All three individuals were otherwise in good health
except for subject *' 1 who vas recovering from homologous serum jaundice.
This complication had developed one month following blood tranfusion received
at the time of surgery, and the study with cortisone -4-C'4 ointment was begun
13 days later when her liver functiou tests were as follows: serum bilirnbin
direct 0.79 mgm. %; serum bilirnbin indirect 0.99 mgm. %; alkaline phosphatase
7.6 units %; thymol flocculation 1+; cephalin flocculation negative. The results
of liver function studies for subjects 2 and 3 were normal.
7.5 microcuries of cortisone -4-C'4 acetatet weighing 6.30 mgm. and having
a specific activity of 0.49pc/m mole were incorporated with 6.27 mgm. of non-
radioactive "carrier" cortisone acetate into 0.5 Gm. of a cholesterolized petro-
* From the Section of Dermatology, University of Chicago, Chicago, Illinois.
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TABLE 1
Subject no. 1
Urine
(24 hours specimens) *1 *2 *3 *4 *5 *6 *7 *8
Planchet net counts per minute
(actual count minus back-
ground) 52 31 27 23 ' 8 31f N.S.t
Calculated total disintegrations
per minute (24 hour specimens). 1191 381 384 393 * 193 845t
* Specimen used for another analysis—see text.
t Specimen collected the 3rd day after removal of dressing and residual ointment.
Not significant. Specimen collected the 7th day after removal of dressing and residual
ointment.
TABLE 2
Subject no. 2
Urine
(24 hour specimens) *1 *2 *3 *4 *5 *6 *7 *8 *9
Planchet net counts per minute
(actual count minus back-
ground)
Calculated total disintegra-
tions per minute (24 hour
specimens)
46
853
27
286
18
303
23
250
15
252
19
227
10*
192
N.S.t
N.S.t
N.S4
N.S.t
* Specimen collected the 2nd day after removal of dressing and residual ointment.
Not significant. Specimen collected the 4th day after removal of dressing and re-
sidual ointment.
Not significant. Specimen collected the 10th day after removal of dressing and re-
sidual ointment.
latum base. * Application of this 2.5 % cortisone ointment was made to a 39
square centimeter area of normal skin over the flexor aspect of the forearm and
the material was rubbed in sufficiently to provide a thin film over the skin surface.
The amounts applied were 92 mgm. of ointment containing 1.2 mgm. of cortisone
-4-C'4 acetate to subject # 1, 70 mgm. of ointment containing 0.9 mgm. of corti-
sone -4-C'4 acetate to subject #2 and 55 mgm. of ointment containing 0.6 mgm.
of cortisone -4-C'4 acetate to subject * 3. The sites of application remained
covered for 6—7 days with a perforated aluminum eye patch taped firmly to the
skin, and daily 24-hour urine specimens were collected throughout this period.
The dressings were then removed and the skin thoroughly cleansed of residual
ointment with ether soaked cotton pledgets. Collection of 24-hour urine speci-
mens was continued intermittently as shown in tables # 1—3.
* This base contains petrolatum, cholesterol, multiwax and mineral oil. It is the standard
vehicle for the hydrocortisooe ointment preparations of the Upjohn Company, Kalamazoo,
Michigan.
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TABLE 3
Subject no. S
Urine
24 (hour specimens) 51 52 53 54 55 55 57 55 59 510
Planchet net counts per
minute (actual count
minus background)
Calculated total disintegra-
tions per minute (24 hour
specimens)
52
452
45
380
75
764 *
46
728
29
485
25
370
35t
410t
li
322t
N.S.
N.S.
* Incomplete sample.
I Specimen collected the 2nd day after removal of dressing and residual ointment.
t Specimen collected the 3rd day after removal of dressing and residual ointment.
§ Not significant. Specimen collected the 5th day after removal of dressing and re-
sidual ointment.
The 17-Ketosteroid fraction of the urine was isolated by the method of Koch
(8) as follows:
1) 38% hydrochloric acid was added to each 24-hour urine specimen in an
amount equal to 10 % of the volume of the specimen. The resultant mixture was
boiled for 15 minutes under a reflux condenser and allowed to cool.
2) 500 cc. aliquots of the acidified urine were extracted 3 times for 3 minutes
each with 75 cc. of anhydrous absolute ether.
3) The ether extraction series were thea combined and washed successively
with distilled water, a saturated solution of sodium bicarbonate, a 10 % solution
of sodium hydroxide, 2N sulfuric acid, and again with distilled water.
4) The ether was distilled off and the residue redissolved in absolute alcohol.
After the alcohol was blown off with nitrogen, the remaining extract was weighed,
and an aliquot of known weight was transferred to a planchet for measurement
of radioactivity in a gas flow counter.
Disintegrations per minute were calculated for each total extract on a weight
basis following determinations of net counts per minute for the planchet sample.
RESULTS
Within 24 hours after application of the 4-C'4 labeled cortisone, significant
radioactivity was found in the urine of the 3 individuals tested (see tables 1—3).
Subjects 1 and 2, furthermore, showed their peak excretion of radioactive
material during this first 24-hour period. Each of the 3 subjects showed continu-
ing but relatively low levels of activity in all urine extracts for the 6—7 period in
which the ointment sites remained covered. After removal of the ointment,
radioactivity was still observed in urine extracts up to 3 days later, but beyond
that time significant activity was not detectable in the urine of any of the sub-
jects tested. Examination by enzymatic hydrolysis (9) of the 5th 24-hour urine
specimen from subject , 1 revealed that after paper chromatography and elution
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tetrahydrocortisone had a specific activity of 0.0233 c/m mole.* This analysis
clearly indicated the presence of radioactivity in a urinary compound which is
probably the chief excretion product of cortisone.
In 2 instances (subjects ,t' 2 and ,' 3) ether recovery of some of the removed
ointment showed high radioactivity, indicating that appreciable amounts of
cortisone-4-C'4 remained on the skin surface throughout the test period.
The moderate impairment in liver function tests noted in the first patient
seemed to produce no appreciable effects on the excretion pattern observed. Also
of interest in this individual was the suddenly increased activity found in extract
7. This extract was prepared from the first urine specimen obtained 3 days
after vigorous removal of the ointment from the skin surface with ether-soaked
cotton pledgets. In subject Y 3 there was also a suggestion of a rise in cortisone
excretion after cleansing of the treated skin site with ether. Here extract 8,
obtained 48 hours after ointment removal, showed maintenance of previous
activity levels where a sharp drop would ordinarily have been expected. No
increase in urine activity was seen in subject 2 after removal of the ointment.
The excretion pattern observed in subject ,t' 3 varied somewhat from that
seen in the other persons studied. There was no distinctly high 24-hour excretion
peak, and the period of greatest radioactivity in the urine was found on the 3rd
and 5th days rather than during the first 24 hours. In this regard it should be
mentioned that the changes in urinary activity coincided with sharp fluctuations
in urine volume. The patient's urine output was 600 cc. for each of the first 24-
hour periods following self-imposed restriction of fluids because of discomfort in
using the bedpan. From the 3rd day fluids were forced and the urine output
doubled. It has been stated (10) however, that daily excretion of 17-hydroxy-
corticoids is largely independent of urine volume, so the importance of this
observation and the significance of the different excretion pattern seen in this
patient remain undetermined.
DISCUSSION
The previous study with topically applied hydrocortisone-4-C'4 (7) showed
some urinary radioactivity in the first 24-hour period, peak excretion of active
material in the second 24 hours, and continued low levels of urinary excretion
until the ointment was removed from the skin surface. The urinary excretion
pattern of topically applied cortisone -4-C'4, then, is similar to hydrocortisone
except for peak excretion in the first rather than the second 24-hour period. The
occurrence of highest urinary activity at different time intervals is consistent
with the findings of Sandberg et at (10) that after oral administration of these
hormones the steroid degradation products of cortisone appeared in the urine
at a more rapid rate than the degradation products of hydrocortisone.
The distinct elevation in excretion of both hormones shortly after application,
and the rise in cortisone -4-C'4 excretion after vigorous removal of the ointment
probably reflect transfollicular absorption from mechanical introduction of
radioactive hormone into the hair follicles. The persistent but lower levels of
* This analysis was carried out by Dr. Harold Werbin, Argonne Cancer Research
Hospital.
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urine activity throughout the period of ointment contact with the skin indicate
continuous transepidermal or transfollicular absorption of hormone. This as-
sumption is supported by the recovery from subjects #2 and #3 of appreciable
quantities of cortisone -4-C'4 still present in the ointment 6—7 days after applica-
tion. Scott and Kalz (11) have conclusively shown by autoradiography that
percutaneous absorption of hydrocortisone-4-C'4 occurs by both the trans-
epidermal and transfollicular routes, and the present investigation indicates that
cortisone is similarly absorbed.
Finally, both the hydrocortisone-4-C'4 and cortisone-4-C'4 studies show
that only a small fraction of the applied hormones—less than 1 % by the de-
scribed procedure—could be demonstrated in the urine.
Since cortisone and hydrocortisone are now shown to be similarly absorbed
qualitatively and quantitatively through the skin, it is apparent that the con-
trasting therapeutic effectiveness of these hormones is due to differences in their
metabolism by the skin. In this regard the work of Wilson and her associates
(12, 13) is of great interest. It has been found that hydrocortisone is far more
active than cortisone in suppressing inflammation when injected into joints
with synovial effusions (14, 15) although both steroids are equally effective in
the treatment of rheumatoid arthritis when given systemically. Wilson et at
(12, 13) demonstrated that the synovial cavity contains enzyme systems capable
of producing a variety of steroid metabolites following local injection of either
cortisone or hydrocortisone, but that the pattern of the metabolites as indicated
by paper chromatography was quite different with these two hormones. Some
conversion of cortisone to hydrocortisone occurred in the synovial cavity but,
since cortisone does not have anti-inflammatory activity in rheumatoid synovial
tissue, the authors concluded that the local effectiveness of hydrocortisone
probably involves the low yield production of a metabolite specific for this hor-
mone.
Only comparable studies of the cutaneous metabolism of cortisone and hydro-
cortisone will provide the answer to the distinctly different topical therapeutic
effects obtained with these two hormones. The isolation and identification of the
postulated anti-inflammatory steroid metabolites in the skin should be of con-
siderable significance.
SUMMARY
1) Percutaneous absorption of cortisone through normal human skin has been
established by detection of radioactivity in the urine following topical application
of cortisone-4-C'4 acetate incorporated into an ointment base. Peak excretion of
cortisone occurred in the first 24 hours after application, but lower levels of
radioactivity persisted throughout the 6—7 day experimental period.
2) Comparison with previous studies of the percutaneous absorption of hydro-
cortisone-4-C'4 indicates that penetration of cortisone and hydrocortisone into
the skin are closely similar, qualitatively and quantitatively.
3) From the latter observation the inefficacy of topical cortisone therapy, in
contrast to hydrocortisone, implies formation in the skin of one or more potent
anti-inflammatory metabolites specific for hydrocortisone.
216 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
REFERENCES
1. GOLDMAN, L., THOMPSON, R. G. AND TaIcE, E. R.: Cortisone acetate in skin disease;
local effect in skin from tropical application and local injection. Arch. Dermat. &
Syph., 65: 177, 1952.
2. SULZBEEGEE, M. B. AND BAEE, R. L.: Present Status of ACTH, Cortisone, and Com-
pound F in Dermatologic Management: A Guide for the General Practitioner. In:
Year Book of Dermatology and Syphilology, 1952, p. 7—21. Chicago, The Year Book
Publishers, 1953.
3. SULZBEEGEE, M. B. AND WITTEN, V. H.: The effect of topically applied compound F
in selected dermatoses. J. Invest. Dermat., 19: 101, 1952.
4. SULZBEEGEE, M. B., WITTEN, V. H. AND SMITH, C. C.: Hydrocortisoue (Compound F)
acetate ointment in dermatological therapy. J. A. M. A., 151: 468, 1953.
5. RomNsoN, Ja., H. M. AND ROBINSON, H. C. V.: Treatment of dermatoses with local
application of hydrocortisone acetate. J. A. M. A., 155: 1213, 1954.
6. MALKINSON, F. D. AND WELLS, G. C.: Clinical experience with hydrocortisone oint-
ment. Brit. J. Dermat., 66: 300, 1954.
7. MALKINSON, F. D. AND FERGUSON, E. H.: Preliminary and Short Report: Percutaneous
absorption of hydrocortisone-4-C'4 in two human subjects. J. Invest. Dermat., 25:
281, 1955.
8. LANOAU, R. L.: Diagnostic significance and laboratory methods in determination of
the 17•ketosteroids. Am. J. Clin. Path., 19: 424, 1949.
9. GLENN, E. M. AND NELSON, D. H.: Chemical method for the determination of 17-
hydroxycorticosteroids and 17-ketosteroids in urine following hydrolysis with fi-
glucuronidase. J. Clin. Endocrinol. and Metab., 13: 911, 1953.
10. SANDBEEO, A. A., NELSON, D. H., GLENN, M. E., TYLER, F. H. AND SAMUEL5, L. T.:
17-hydroxycorticosteroids and 17-ketosteroids in urine of human subjects: Clinical
application of a method employing 3-glucuronidase hydrolysis. J. Clin. Endocrinol.
and Metab., 13: 1445, 1953.
11. SCOTT, A. AND KALZ, F.: The penetration and distribution of C'4-hydrocortisoue in
human skin after its topical application. J. Invest. Dermat., 26: 149, 1956.
12. WILSON, H., GLYN, J., SCULL, E., McEwEN, C. AND ZIFF, M.: Rate of disappearance
and metabolism of hydrocortisone and cortisone in the synovial cavity in rheuma-
toid arthritis. Proc. Soc. Exper. Biol. & Med., 83: 648, 1953.
13. WILSON, H., FAIRBANKS, R., SCIALABBA, D., MCEwEN, C. AND ZIFF, M.: Metabolites
of hydrocortisone and cortisone in synovial fluid in rheumatoid arthritis. J. Clin.
Endocrinol. and Metab., 16: 87, 1956.
14. HOLLANDEE, J. L., BEOUN, JR., E. M., JES5AE, R. A. AND BEOUN, C. Y.: Hydrocorti-
soue and cortisone injected into arthritic joints: Comparative effects of and use of
hydrocortisone as a local anti-arthritic agent. J. A. M. A., 147: 1629, 1951.
15. ZIFF, M., SCULL, E., FORD, D., MCEwEN, C. AND BUNIN, J. J.: Effects in rheumatoid
arthritis of hydrocortisone and cortisone injected intra-articularly. Arch. Jut. Med.,
90: 774, 1952.
DISCUSSION
Dn. LEON GOLDMAN (Cincinnati, Ohio): This is a very interesting and a very
important study. It indicates the necessity for continuing studies of this type.
There is a question about local injection of cortisone into the guinea pig skin
because local injection here does inhibit local inflammatory reaction. We did a
few experiments with local injection of cortisone into the skin of guinea pigs and
chromatograms in our experiments showed only cortisone. We thought from these
studies that the guinea pig skin was unable to metabolize cortisone to hydro-
cortisone.
